Physician profile
Brian D Jones
NPI 1033174222
$6,122.80
in general payments reported to CMS, 2019-2025
17 companies · $1,687 in 2025
The $1,687 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $715 · 2020: $403 · 2021: $757 · 2022: $585 · 2023: $762 · 2024: $1,215 · 2025: $1,687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,615 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,615.18 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,730.46 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,480.84 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $414.33 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $399.91 | 2020-2025 | Austedo Xr, Uzedy |
| Lundbeck LLC | $356.30 | 2019-2025 | Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $332.60 | 2024-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $269.42 | 2021-2025 | Ingrezza |
| Allergan, INC. | $216.52 | 2019-2020 | |
| Alkermes, INC. | $214.49 | 2021-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $193.46 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $150.31 | 2024-2025 | Cobenfy |
| Braeburn INC. | $113.10 | 2024 | Brixadi |
| Takeda Pharmaceuticals U.S.A., INC. | $111.14 | 2019-2024 | Trintellix |
| Vanda Pharmaceuticals INC. | $59.17 | 2019-2025 | Fanapt, Hetlioz |
| Indivior INC. | $42.91 | 2019-2024 | Sublocade |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.47 | 2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $16.37 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.